80% of complications arise as a result of CIED infection1
Between 1993 and 2008, there was a 96% increase in the implantation of CIEDs.
This coincided with a 210% increase in CIED infections.2
Reduce the risk of CIED infections in the first instance
TauroPace reduces the risk of CIED-related infections, which can cost the NHS as much as £30,958 per patient.3
Prevent CIED-related infections, without the problem of antibiotic resistance.
TauroPace contains taurolidine which kills bacteria and funghi within 2 hours of administering,4 and which will also aid in preventing biofilm formation.4
Whereas current antibiotic prophylaxis is falling short due to bacterial resistance2,5, taurolidine rarely causes side effects; 6 and bacterial resistance against taurolidine has never been observed. 7,8
To learn more about the benefits of using TauroPace in your department, join our series of webinars with Benito Baldauf, MD
1. Topkara, V.K., et al. (2010) Infectious complications in patients with left ventricular assist device: etiology and outcomes in the continuous-flow era. Ann Thorac Surg. 90(4):1270–1277
2. Greenspon, A.J., et al. (2011) 16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008. J Am Coll Cardiol. 30;58(10):1001-6
3. Ahsan, S.Y., et al. (2014) A simple infection control protocol to reduce serious cardiac device infections. Europace. 16(10):1482–9
4. TauroPharm: Data on File
5. Baddour, L.M., et al. (2010) Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation. 2010 Jan 26;121(3):458-77
6. Liu, Y., et al. (2013) Taurolidine lock solutions for the prevention of catheter-related bloodstream infections: a systematic review and meta-analysis of randomized controlled trials. PLoS ONE. 8(11):e79417
7. Olthof, D., et al. (2013) Absence of microbial adaption to taurolidine in patients on home parenteral nutrition who develop catheter related bloodstream infections and use taurolidine lock. Clin Nutr. 32: 538–542.
8. Torres-Viera, C., et al. (2000) Activities of Taurolidine In Vitro and in Experimental Enterococcal Endocarditis. Antimicrobial Agents and Chemotherapy. 44 (6): 1720–1724.